# Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

> **NCT07363577** · PHASE3 · RECRUITING · sponsor: **LB Pharmaceuticals Inc.** · enrollment: 456 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LB-102 (50 mg tablet)
- **DRUG:** LB-102 (100 mg tablet)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07363577
- **Lead sponsor:** LB Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2027-06
- **Final completion:** 2027-10
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363577, "Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07363577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*